Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infirst's 'ChocoCough' gets £25 million backing

This article was originally published in Scrip

Executive Summary

Infirst Healthcare, a new company led by the former president of GlaxoSmithKline's European consumer healthcare business, has raised £25 million from Invesco Asset Management to launch products into the cough/cold and pain consumer healthcare markets.Infirst was spun out of the privatelyheld UK-based drug discovery group SEEK, which was founded in 2004 and previously known as PepTcell. SEEK and its US partner Pernix Therapeutics had initially hoped to find a partner to move the assets forward (, 28 March 2011).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts